Published: Apr 05, 2021
April 5, 2021 12:00 UTC
Quidel Corporation, the Nation’s Leading Developer of Rapid Lyme Disease Testing, Cautions Americans to be Vigilant, Take Precautions and Get Tested if in Doubt
SAN DIEGO (BUSINESS WIRE) As America slowly and hopefully extricates itself from the coronavirus pandemic, another health concern lies just around the corner: the start of Lyme disease season. To complicate matters, Lyme disease is one of the distinct underlying conditions that make those afflicted more vulnerable for coronavirus complications.
“The warm weather of spring and summer makes everyone want to get outdoors and never more so than this year when so many of us have spent the past 12 months hunkered down in our own homes,” says Judi Tilghman, Ph.D., vice president of technology assessment at
Published: Apr 06, 2021
Heart failure and asthma studies will pilot a new digital health platform to help improve outcomes for patients with chronic diseases
WILMINGTON, Del. (BUSINESS WIRE) AstraZeneca has entered into a collaboration agreement with Massachusetts General Hospital (MGH), leveraging robust data and clinical best practices to create digital health solutions that address today’s most urgent healthcare challenges. Catalyzed by the COVID-19 pandemic and a shared mission to improve care for patients with chronic illness, this novel partnership is focused on creating and clinically validating patient-centric digital health solutions and establishing a new standard of care for chronic illness management outside of a clinical setting.
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE)
Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Company, with effect 24 June 2021. Opthea has initiated a search for a permanent replacement with requisite expertise in financial reporting and company secretarial duties for a dual ASX and Nasdaq listed company.
Mr Tonroe leaves Opthea at a time of corporate growth and emerging presence in the US to align with the recent listing on Nasdaq and initiation of the Company’s global Phase 3 clinical development program for OPT-302 in wet age-related macular degeneration (wet AMD).
Published: Apr 02, 2021
SAN DIEGO, Calif., April 2, 2021 /PRNewswire/ Together with scientists from the University of California, San Diego (UCSD), Global Cancer Technology (GCT) and the renowned Barrow Neurological Institute, pre-clinical studies have begun towards the commercialization of a new glioblastoma treatment. Glioblastoma is a rare cancer, occurring in fewer than one in 10,000 cases; however, it is among the most aggressive and lethal cancers. Fewer than 25% of those diagnosed will survive one year and fewer than 5% survive five years. Incidence in men is slightly higher than in women with the average age of diagnosis around 60. Glioblastoma is on the rise where contributing factors including ionizing radiation, air pollution, and an aging population. Each year, more than 17,000 Americans die from this incurable disease.
Published: Apr 05, 2021
SOUTH ORANGE, NJ, April 05, 2021 (GLOBE NEWSWIRE) via
NewMediaWire Nephros Inc.. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary results for the first quarter of 2021.
Revenue for the quarter ended March 31, 2021 is expected to be $2.7 million, representing growth of 17% over the prior period, and 8% over the same period in 2020.
“Despite the pandemic, Nephros accomplished a milestone, recording the highest ever, first-quarter revenue, and the third-highest quarterly revenue in our history. These results, represented by strength in all of our filtration markets – Healthcare, Dialysis, and Commercial – reflect the growth of our underlying business and steady, long-term focus on taking care of our strategic partners and customers,” said Andy Astor, Chief Executive Officer of Nephros. “As more of the country is vaccin